|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||89.79 - 92.45|
|52-week range||73.31 - 114.80|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||17.01|
|Forward dividend & yield||3.52 (3.92%)|
|Ex-dividend date||06 May 2022|
|1y target est||123.28|
Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.
Following FDA approval, Provention Bio's (PRVB) Tzield is the first disease-modifying therapy in T1D. Tzield can delay the onset of stage 3 T1D in individuals aged eight years and older.
Roche's (RHHBY) late-stage Alzheimer's disease study on key pipeline candidate, gantenerumab fails. Sanofi's (SNY) Enjaymo to treat a rare form of anemia gets approval in Europe.